Big Pharma Outlook: CEOs Making the Moves
By

By
As the industry moves further into 2026, what are larger issues impacting industry and company performance? .A view from the C-suite.

Industry Radar: What’s Next in US Drug Pricing
By

By
A bevy of news on the US drug pricing front: the debut of TrumpRx, a direct-to-patient drug purchasing channel, continued policy moves to most favored drug nation pricing, reforms of PBMs, and the latest in IRA

A Global View: Bio/Pharma Mfg Investments
By

By
The wave of US-based manufacturing investments has garnered the headlines, but what are key ex-US capital projects by pharma companies? DCAT Value Chain Insights provides a global roundup. 

Next Rx Drugs Selected for US Price Negotiations 
By

By
The US government released this week the next 15 Rx drugs subject to price negotiations under the Inflation Reduction Act, the landmark legislation that put into place drug pricing reforms…

Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? 
By

By
What are the pressing issues shaping the market for fine chemicals and pharma ingredients in 2026—the challenges and the opportunities? Senior executives from CDMOs share their perspectives.  

EU Advances Critical Medicines Act for Securing EU API Supply
By

By
The European Parliament has endorsed its position on the Critical Medicines Act, setting the stage to finalize the law to assure security of supply for essential medicines in the EU.

CDMO/CMO Outlook: 2026 in Bio/Pharma Outsourcing
By

By
What can CDMOs/CMOs expect in 2026? DCAT Value Chain Insights looks at the issues shaping the market for bio/pharmaceutical outsourcing in the coming year: key trends, fundamentals, and the variables influencing the sector’s performance.

The DCAT Pulse: The Tariff Outlook & Pharma
By

By
Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing…

Bio/Pharma Outlook 2026: The Year Ahead
By

By
What are the key issues on the bio/pharmaceutical industry’s radar in 2026? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.

Have Your Company Be a Newsmaker at DCAT Week
By

By
Does your company have major company news that it would like to share at DCAT Week? DCAT Member Companies are invited to apply to present at the Member Company Announcement Forum, a valuable platform in which senior executives make significant news announcements.